Acute Myeloid Leukemia

Enrollment has begun on a phase 3 clinical trial assessing the safety and efficacy of an investigational cell therapy in patients with acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndromes.

The findings support future studies of assessing the safety and efficacy of the novel drug-chemotherapy combination as a maintenance strategy following stem cell transplantation across a range of blood cancers, according to the study authors.

Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.

Treatment with a novel monotherapy in a patient with relapsed/refractory acute myeloid leukemia was effective enough that a successful, as indicated by a significant reduction in bone marrow blasts, stem cell transplant was performed.

A trial to examine BMF-219 in patients with relapsed or refractory acute leukemias has begun recruiting patients across multiple U.S. states.

All clinical trials investigating the combination of magrolimab and the chemotherapy Onureg have been paused due to unforeseen serious side effects experienced by patients with various blood cancers receiving the treatment.

A phase 3 trial has begun to examine entospletinib, a selective inhibitor, as a treatment for patients with newly diagnosed NPM1-mutated acute myeloid leukemia.

Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.

The immunotherapy Kymriah offered similar benefits in patients younger than and older than 18 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

A phase 2 trial of aspacytarabine (BST-236) was initiated in patients with AML and MDS.

Study results showed that CPI-613 did not improve survival in patients with metastatic adenocarcinoma of the pancreas.

An abundance of clinical trials is giving patients with acute myeloid leukemia (AML) hope for a better future.

Patients who are immunocompromised, such as patients with blood cancers, may get the boosted immunity needed to reduce their risk for contracting COVID-19 and hospitalization for compilations related to the virus.

“We are fortunate now to live in an era where we have nine new drugs approved (for AML) just in the last five years,” says an expert from The University of Texas MD Anderson Cancer Center.

“More and more (patients and physicians) need to work together in partnership throughout the cancer journey in order to optimize and make the journey the best possible that we can for every single patient,” says an expert from the Roswell Park Comprehensive Cancer Center.

A woman shares the story of her journey with multiple cancer types, including the same one that her mother died from.

Scientists have identified a potentially valuable genetic target in children with acute myeloid leukemia that could lead to further studies in immunotherapy drugs for the disease.

An analysis of more than 3.5 million children born between January 1996 and December 2016 demonstrated a stronger association between Down syndrome and acute myeloid leukemia risk than has been previously reported.

Treatment with a novel therapy as a single agent, or in combination with Venclexta, demonstrated a manageable safety profile and antileukemic effects in patients with relapsed/refractory acute myeloid leukemia. The study authors, however, note that more research is needed.

Compared to a hypomethylating agent alone, combining the agent with Venclexta improved complete remission rates in patients with blast-phase myeloproliferative neoplasm.

Patients with acute myeloid leukemia experience post-traumatic stress disorder symptoms including intrusion, avoidance and hypervigilance one month after diagnosis.

The agency granted approval to the revised label of Vyxeos to now include treatment for newly diagnosed therapy-related acute myeloid leukemia or disease with myelodysplasia-related changes in pediatric patients aged 1 and older.

Onureg, an oral form of the chemotherapy azacitidine, in older patients with acute myeloid leukemia who were in remission after chemotherapy contributed to longer survival outcomes, compared to placebo.

The FDA has lifted a partial clinical hold on a phase 2 trial evaluating a novel therapy in patients with acute myeloid leukemia following an allogenic stem cell transplant.

Here is a list of some recent trials that launched within the cancer space in December.

Here are the top 10 FDA oncology drug approvals that you may have missed this year.

A roundup of some of the most read news and updates in acute myeloid leukemia in 2020 from CURE®.

Here is a list of some recent trials that launched within the cancer space in November.

After granting accelerated approval in 2018, the Food and Drug Administration approved Venclexta in combination with Vidaza, Dacogen or low dose cytarabine in newly diagnosed patients with AML.